Interleukin-1β modulates smooth muscle cell phenotype to a distinct inflammatory state relative to PDGF-DD via NF-κB-dependent mechanisms
Open Access
- 1 April 2012
- journal article
- research article
- Published by American Physiological Society in Physiological Genomics
- Vol. 44 (7) , 417-429
Abstract
Smooth muscle cell (SMC) phenotypic modulation in atherosclerosis and in response to PDGF in vitro involves repression of differentiation marker genes and increases in SMC proliferation, migration, and matrix synthesis. However, SMCs within atherosclerotic plaques can also express a number of proinflammatory genes, and in cultured SMCs the inflammatory cytokine IL-1β represses SMC marker gene expression and induces inflammatory gene expression. Studies herein tested the hypothesis that IL-1β modulates SMC phenotype to a distinct inflammatory state relative to PDGF-DD. Genome-wide gene expression analysis of IL-1β- or PDGF-DD-treated SMCs revealed that although both stimuli repressed SMC differentiation marker gene expression, IL-1β distinctly induced expression of proinflammatory genes, while PDGF-DD primarily induced genes involved in cell proliferation. Promoters of inflammatory genes distinctly induced by IL-1β exhibited over-representation of NF-κB binding sites, and NF-κB inhibition in SMCs reduced IL-1β-induced upregulation of proinflammatory genes as well as repression of SMC differentiation marker genes. Interestingly, PDGF-DD-induced SMC marker gene repression was not NF-κB dependent. Finally, immunofluorescent staining of mouse atherosclerotic lesions revealed the presence of cells positive for the marker of an IL-1β-stimulated inflammatory SMC, chemokine (C-C motif) ligand 20 (CCL20), but not the PDGF-DD-induced gene, regulator of G protein signaling 17 (RGS17). Results demonstrate that IL-1β- but not PDGF-DD-induced phenotypic modulation of SMC is characterized by NF-κB-dependent activation of proinflammatory genes, suggesting the existence of a distinct inflammatory SMC phenotype. In addition, studies provide evidence for the possible utility of CCL20 and RGS17 as markers of inflammatory and proliferative state SMCs within atherosclerotic plaques in vivo.Keywords
This publication has 80 references indexed in Scilit:
- Genetic Deletion of Chemokine Receptor Ccr6 Decreases Atherogenesis inApoE-Deficient MiceCirculation Research, 2011
- Diabetic conditions promote binding of monocytes to vascular smooth muscle cells and their subsequent differentiationAmerican Journal of Physiology-Heart and Circulatory Physiology, 2010
- Inflammation in AtherosclerosisJACC, 2009
- Sp1-dependent activation of KLF4 is required for PDGF-BB-induced phenotypic modulation of smooth muscleAmerican Journal of Physiology-Heart and Circulatory Physiology, 2009
- PDGF-DD, a novel mediator of smooth muscle cell phenotypic modulation, is upregulated in endothelial cells exposed to atherosclerosis-prone flow patternsAmerican Journal of Physiology-Heart and Circulatory Physiology, 2009
- Systematic and integrative analysis of large gene lists using DAVID bioinformatics resourcesNature Protocols, 2008
- Myocardin inhibits cellular proliferation by inhibiting NF-κB(p65)-dependent cell cycle progressionProceedings of the National Academy of Sciences, 2008
- Distinct roles of E2F proteins in vascular smooth muscle cell proliferation and intimal hyperplasiaProceedings of the National Academy of Sciences, 2007
- GenePattern 2.0Nature Genetics, 2006
- The pathogenesis of atherosclerosis: a perspective for the 1990sNature, 1993